The FDA has placed a hold on BioNTech’s phase 1/2a trial, pausing the company’s efforts to develop a RNA-based vaccine for ...

Under President Donald Trump’s administration, the Department of Government Efficiency (DOGE) has reportedly terminated ...

Private equity giant Blackstone is going big on Japan, acquiring a majority stake in the country’s leading contract research ...

Philips is pulling from the market an implant designed to help repair the interior of damaged blood vessels, following a serious product recall. | Philips is pulling from the market an implant ...

Global contract research organization IQVIA is looking to simplify workflows for its clinical trial investigators with a new ...

Illumina has been barred from exporting its DNA sequencers to China, which closed | Illumina has been barred from exporting ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy (DMD) therapy in ...

Atara Biotherapeutics is halving its headcount as it navigates the fallout from the FDA’s move to halt trials of the ...

A one-time injection of a novel gene therapy was able to save mice and a newborn calf from succumbing to maple syrup urine ...

Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.27 billion) that Sofinnova Partners has ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. | Biohaven’s bipolar ...